Back to search results

Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia

IsraelCompletedPHASE2

Conditions

Chronic Myelogenous Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Local Institution, Birmingham, Alabama, United States

  • Local Institution, Anaheim, California, United States

  • Local Institution, Los Angeles, California, United States

  • Local Institution, Stanford, California, United States

  • Local Institution, Vallejo, California, United States

  • Local Institution, Jacksonville, Florida, United States

  • Local Institution, Tampa, Florida, United States

  • Local Institution, Atlanta, Georgia, United States

  • Local Institution, Chicago, Illinois, United States

  • Local Institution, Kansas City, Kansas, United States

  • Local Institution, Baltimore, Maryland, United States

  • Local Institution, Boston, Massachusetts, United States

  • Local Institution, Detroit, Michigan, United States

  • Local Institution, St Louis, Missouri, United States

  • Local Institution, Hackensack, New Jersey, United States

  • Local Institution, New York, New York, United States

  • Local Institution, Portland, Oregon, United States

  • Local Institution, Pittsburgh, Pennsylvania, United States

  • Local Institution, Nashville, Tennessee, United States

  • Local Institution, Dallas, Texas, United States

  • Local Institution, Houston, Texas, United States

  • Local Institution, Buenos Aires, Buenos Aires, Argentina

  • Local Institution, Córdoba, Córdoba Province, Argentina

  • Local Institution, St Leonards, New South Wales, Australia

  • Local Institution, South Brisbane, Queensland, Australia

  • Local Institution, East Melbourne, Victoria, Australia

  • Local Institution, Parkville, Victoria, Australia

  • Local Institution, Wien, Australia

  • Local Institution, B-Leuven, Belgium

  • Local Institution, Edegem, Belgium

  • Local Institution, Rio de Janeiro, Rio de Janeiro, Brazil

  • Local Institution, São Paulo, São Paulo, Brazil

  • Local Institution, Campinas, Brazil

  • Local Institution, Toronto, Ontario, Canada

  • Local Institution, Aarhus, Denmark

  • Local Institution, Helsinki, Finland

  • Local Institution, Lille, France

  • Local Institution, Lyon, France

  • Local Institution, Nantes, France

  • Local Institution, Paris, France

  • Local Institution, Pessac, France

  • Local Institution, Poitiers, France

  • Local Institution, Strasbourg, France

  • Local Institution, Hamburg, Germany

  • Local Institution, Mainz, Germany

  • Local Institution, Mannheim, Germany

  • Local Institution, Ramat Gan, Israel

  • Local Institution, Bologna, Italy

  • Local Institution, Naples, Italy

  • Local Institution, Orbassano, Italy

  • Local Institution, Roma, Italy

  • Local Institution, Nijmegen, Netherlands

  • Local Institution, Rotterdam, Netherlands

  • Local Institution, Trondheim, Norway

  • Local Institution, Lima, Lima Province, Peru

  • Local Institution, Quezon City, Philippines

  • Local Institution, Singapore, Singapore

  • Local Institution, Jeollanam-Do, South Korea

  • Local Institution, Kyunggi-Do, South Korea

  • Local Institution, Seoul, South Korea

  • Local Institution, Gothenburg, Sweden

  • Local Institution, Lund, Sweden

  • Local Institution, Umeå, Sweden

  • Local Institution, Uppsala, Sweden

  • Local Institution, Basel, Switzerland

  • Local Institution, Taipei, Taiwan

  • Local Institution, Taoyuan, Taiwan

  • Local Institution, Bangkok, Thailand

  • Local Institution, Glasgow, Central, United Kingdom

  • Local Institution, London, Greater London, United Kingdom

Study leads

  • Bristol-Myers Squibb

    Study Director

    Bristol-Myers Squibb

View source on ClinicalTrials.gov(opens in a new tab)